Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;80(10):3460-70.
doi: 10.1128/IAI.00230-12. Epub 2012 Jul 23.

Protein A-specific monoclonal antibodies and prevention of Staphylococcus aureus disease in mice

Affiliations

Protein A-specific monoclonal antibodies and prevention of Staphylococcus aureus disease in mice

Hwan Keun Kim et al. Infect Immun. 2012 Oct.

Abstract

Staphylococcus aureus is a leading cause of human soft tissue infections and bacterial sepsis. The emergence of antibiotic-resistant strains (methicillin-resistant S. aureus [MRSA]) has prompted research into staphylococcal vaccines and preventive measures. The envelope of S. aureus is decorated with staphylococcal protein A (SpA), which captures the Fcγ portion of immunoglobulins to prevent opsonophagocytosis and associates with the Fab portion of V(H)3-type B cell receptors to trigger B cell superantigen activity. Nontoxigenic protein A (SpA(KKAA)), when used as an immunogen in mice, stimulates humoral immune responses that neutralize the Fcγ and the V(H)3(+) Fab binding activities of SpA and provide protection from staphylococcal abscess formation in mice. Here, we isolated monoclonal antibodies (MAbs) against SpA(KKAA) that, by binding to the triple-helical bundle fold of its immunoglobulin binding domains (IgBDs), neutralize the Fcγ and Fab binding activities of SpA. SpA(KKAA) MAbs promoted opsonophagocytic killing of MRSA in mouse and human blood, provided protection from abscess formation, and stimulated pathogen-specific immune responses in a mouse model of staphylococcal disease. Thus, SpA(KKAA) MAbs may be useful for the prevention and therapy of staphylococcal disease in humans.

PubMed Disclaimer

Figures

Fig 1
Fig 1
SpAKKAA-specific monoclonal antibodies (MAbs) protect mice against MRSA infection. Cohorts of animals (n = 10) were passively immunized by intraperitoneal injection with either isotype control (IgG2a) or SpAKKAA MAb (3F6) at 20 mg · kg−1. After 24 h, animals were challenged with 5 × 106 CFU of S. aureus MW2. (A) At 15 days postchallenge, animals were euthanized to enumerate the staphylococcal load in kidneys. (B) Serum samples of mice infected for 15 days were analyzed for antibodies against the staphylococcal antigen matrix. ClfA, clumping factor A; ClfB, clumping factor B; FnBPA, fibronectin binding protein A; FnBPB, fibronectin binding protein B; IsdA, iron surface determinant A; IsdB, iron surface determinant B; SdrD, serine-aspartic acid repeat protein D; SpAKKAA, nontoxigenic staphylococcal protein A; Coa, coagulase; EsxA, Ess (early secreted antigen target 6 kDa [ESAT-6] secretion system) extracellular A; EsxB, Ess (ESAT-6 secretion system) extracellular B; Hla, alpha-hemolysin; LukD, leukocidin D; vWbp, von Willebrand binding protein. The values represent the fold increases of samples from MAb 3F6-treated animals over the isotype control animal serum samples (n = 7 for IgG2a, n = 8 for 3F6). Data are the means, and error bars represent ± standard errors of the means (SEM). Results in panels A and B are representative of two independent analyses.
Fig 2
Fig 2
SpA monoclonal antibody (Spa27) fails to elicit protective immunity in mice. (A) ELISA examining the association of SpA MAb (Spa27) and SpAKKAA MAb (3F6) with immobilized wild-type protein A (SpA) and variants lacking immunoglobulin binding via Fcγ (SpAKK), Fab (SpAAA), or Fcγ and Fab (SpAKKAA) (n = 3). (B) Cohorts of animals (n = 9 to 15) were passively immunized by intraperitoneal injection with either mock (PBS), Spa27 at 5 mg · kg−1, or 3F6 at 5 or 50 mg · kg−1. Twenty-four hours postimmunization, animals were challenged with 5 × 106 CFU of S. aureus USA300. Four days postchallenge, animals were euthanized to enumerate the staphylococcal load in kidneys.
Fig 3
Fig 3
Avidity of protein A-specific monoclonal antibodies. Monoclonal antibodies 5A10, 3F6, and 3D11 were incubated with increasing concentrations (0 to 4 M) of ammonium thiocyanate to perturb antigen-antibody-specific interactions. Data are the means, and error bars represent ± SEM. Results are representative of three independent analyses.
Fig 4
Fig 4
SpAKKAA MAb 3F6 binds to Sbi (staphylococcal binder of immunoglobulin). (A) Coomassie blue-stained SDS-PAGE gel revealing the electrophoretic mobility of human immunoglobulin (hIgG, lane 1), purified recombinant Sbi encompassing its immunoglobulin binding domains (Sbi1-4, lane 2), and variant Sbi, which cannot bind hIgG (Sbi1-4/KKAA, lane 3). Using affinity chromatography, His-tagged Sbi1-4 and Sbi1-4/KKAA were eluted from nickel-nitriloacetic acid Sepharose without (−hIgG; lanes 1 to 3) or with (+hIgG; lanes 4 and 5) incubation with human immunoglobulin. (B) ELISA examining the association of immobilized Sbi1-4/KKAA with protein A-specific MAbs (n = 3). Data are the means, and error bars represent ± SEM. Results in panels A and B are representative of three independent analyses.
Fig 5
Fig 5
SpAKKAA-specific MAbs bind wild-type protein A. (A) ELISA examining the binding of immobilized wild-type protein A (SpA) to isotype control antibodies (IgG1, IgG2a, or IgG2b) or SpAKKAA-specific MAbs (5A10, 3F6, and 3D11). (B) Association of horseradish peroxidase (HRP)-conjugated SpAKKAA-specific MAbs (5A10-HRP, 3F6-HRP, and 3D11-HRP) to immobilized SpAKKAA was examined in a plate reader experiment where SpAKKAA was first incubated with isotype control antibodies (IgG1, IgG2a, or IgG2b) or three different SpAKKAA-specific MAbs (5A10, 3F6, and 3D11) to assess the possibility of competitive inhibition for antibodies that bind the same or closely related sites (n = 3). The values at an optical density at 405 nm (OD405) were measured and normalized to the interaction of SpAKKAA and HRP-conjugated SpA-specific MAbs. Data are the means, and error bars represent ± SEM. Data in panels A and B are representative of three independent analyses. Asterisks denote statistical significance (P < 0.05), which was calculated using the two-tailed Student's t test: 5A10-HRP versus 5A10, P = 0.0017; 5A10-HRP versus 3F6, P = 0.0343; 5A10-HRP versus 3D11, P = 0.001; 3F6-HRP versus 5A10, P = 0.0279; 3F6-HRP versus 3F6, P = 0.0001; 3F6-HRP versus 3D11, P = 0.0584; 3D11-HRP versus 5A10, P = 0.0001; 3D11-HRP versus 3F6, P = 0.0005; 3D11-HRP versus 3D11, P = 0.0053.
Fig 6
Fig 6
SpAKKAA MAbs prevent the association of staphylococcal protein A with immunoglobulin. (A) Isotype control antibodies or SpAKKAA MAbs were used to perturb the binding of human IgG to wild-type protein A (SpA) or variants that lack the ability to bind Fcγ (SpAKK) or Fab (SpAAA) immobilized on ELISA plates. The values were normalized to the protein A interaction with human IgG without antibodies (n = 4). (B) Staphylococci were grown to mid-log phase and incubated with either isotype control antibody or MAb 3F6 and followed by the addition of 2 μg wild-type Sbi1-4. Upon incubation, Sbi1-4 consumption was measured by immunoblot using affinity-purified α-SpAKKAA rabbit antibody. The values were normalized to Sbi1-4 sedimentation without antibody (No Ab). (C) Affinity-purified SpA (200 μg) was injected into the peritoneal cavity of mice pretreated with 85 μg (5 mg · kg−1) of either isotype control antibody or MAb 3F6. Animals were euthanized at indicated time points to measure the amount of SpA in circulating blood by immunoblotting with affinity-purified α-SpAKKAA rabbit antibody (n = 3 per time point). The values were normalized to the total amount of SpA injected at 0 min. Data are the means, and error bars represent ±SEM. Results in panels A to C are representative of two independent analyses. The asterisks denotes statistical significance (P < 0.05).
Fig 7
Fig 7
SpAKKAA MAbs promote opsonophagocytic killing of S. aureus in mouse and human blood. (A) Anticoagulated mouse blood was incubated with 5 × 105 CFU S. aureus Newman in the presence of isotype mouse antibody controls or SpAKKAA MAbs (2 μg · ml−1) for 30 min, and survival was measured (n = 3). (B) Anticoagulated human whole blood was incubated with 5 × 106 CFU S. aureus MW2 in the presence of isotype mouse antibody controls or SpAKKAA MAbs (10 μg · ml−1) for 120 min, and survival was measured (n = 3). (C to H) At 60 min of incubation of staphylococci in anticoagulated human blood, clusters of extracellular staphylococci were detected in samples incubated with mouse isotype antibody controls (red arrowheads), whereas staphylococci were found in close proximity to neutrophils (blue arrowheads) in samples with SpAKKAA MAbs. Data are the means, and error bars represent ±SEM. Results in panels A to H are representative of three independent analyses. The asterisks denotes statistical significance (P < 0.05).

References

    1. Atkins KL, et al. 2008. S. aureus IgG-binding proteins SpA and Sbi: host specificity and mechanisms of immune complex formation. Mol. Immunol. 45:1600–1611 - PubMed
    1. Baba T, Bae T, Schneewind O, Takeuchi F, Hiramatsu K. 2008. Genome sequence of Staphylococcus aureus strain Newman and comparative analysis of staphylococcal genomes. J. Bacteriol. 190:300–310 - PMC - PubMed
    1. Baba T, et al. 2002. Genome and virulence determinants of high-virulence community acquired MRSA. Lancet 359:1819–1827 - PubMed
    1. Berberian L, Goodglick L, Kipps TJ, Braun J. 1993. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 261:1588–1591 - PubMed
    1. Berberian L, Valles-Ayoub Y, Sun N, Martinez-Maza O, Braun J. 1991. A VH clonal deficit in human immunodeficiency virus-positive individuals reflects a B-cell maturational arrest. Blood 78:175–179 - PubMed

Publication types

MeSH terms